The former stock portfolio in the House of Representatives Nancy Pelosi achieved great success in 2025, agreeing to the sale of the wider market.
To summarize, Pelosi continued with her trading in Congress in the first quarter of 2025, adding five other shares to its wallet, yet only one name emerges in the profit: Tempus Ai (Nasdaq: TEM).
Receive signals on the shares of the US Congress shares
Shares
Keep aware of the commercial activity of the members of the US Congress. The signal appears based on updates from the home disclosure reports, which teaches you the latest stock transactions.
According to the stadiums, TEM was part of Pelosi deals that were carried out on January 14, 2025, and they were presented on January 17, 2025. Trading included a series of purchase of call options across many major companies.
The American legislator has invested between 50,001 and 100,000 dollars in Tempus AI. Since the purchase, American Health Technology Company shares increased by 34 %.
To put the gains in its right quorum, the standard S&P 500 index has decreased by 13 % since the political deal. As of the time of the press, the TEM value reached $ 42.70, an increase of 24 % of the year.
2025 transactions also included the accumulation of Amazon (Nasdaq: Amzn), alphabet (Nasdaq: Googl), NVIDIA (NASDAQ: NVDA), and Vistra (NYSE: VST).
However, in the latest market data, there are four out of five underwater investments, with losses between 6.12 % to 26.38 %.
Why Tem’s arrow gathered
In general, Tempus AI has benefited from the increasing appetite for artificial intelligence applications (AI) in health care. It focuses on accurate medicine, using artificial intelligence to analyze the vast clinical and molecular data groups, with emerging industry trends.
Meanwhile, the Tempus AI shares increased after the health care company reported the impressive Q4 2024 results and has completed the main acquisition. Revenue jumped by 35.8 % year on an annual basis to $ 200.7 million. Total profits increased by approximately 50 %, and net losses dramatically from $ 50.5 million to $ 13 million.
The Ambry February acquisition of the investor’s confidence, which strengthened the Tempus AI position in the genetic test and careful medicine.
These basics were partially reported by Wall Street in Tipranks‘ TEM ups. According to nine experts, Tempus AI’s shares are likely to trade at an average price of $ 64, with a rise of 50 % in the next 12 months.
Distinctive image via Shutterstock
